[A New Era of Cancer Prevention from Dentistry] Saliva Cancer Risk Testing Bridges Medical Care: Promoting Early Detection via Oral Care to Enhance Health Span
Salivatech presented on the systemic cancer risk assessment and medical referral potential of their "SalivaChecker®" test at the 23rd Annual Meeting of the Japanese Society of Oral Care. By integrating saliva testing into routine oral care, the company aims to promote early cancer detection and enhance health span. The seminar achieved an 85.2% satisfaction rate, highlighting significant professional interest in interdisciplinary cooperation.
📋 Article Processing Timeline
- 📰 Published: May 27, 2026 at 01:00
- 🔍 Collected: May 26, 2026 at 16:31
- 🤖 AI Analyzed: May 26, 2026 at 16:46 (15 min after Collected)
Salivatech (Headquarters: Tsuruoka, Yamagata; CEO: Makoto Sunamura), provider of the saliva-based cancer risk test "SalivaChecker®," announced that Masahiro Sugimoto, Director of Salivatech (and Professor at Keio University Graduate School of Media and Governance), and Remi Onuma, Medical Institutional Sales, presented at a luncheon seminar during the 23rd Annual Meeting of the Japanese Society of Oral Care.
The seminar highlighted the utility of saliva testing in the dental and oral care field, systemic cancer risk assessment through oral care, and bridging patients to appropriate medical treatment to increase health span, drawing significant interest from medical professionals.
Seminar Overview
Seminar Title: Luncheon Seminar "Unlocking Systemic Signals through Oral Care"
Speaker 1: "Perspectives Connecting Oral Care and Systemic Management" - Masahiro Sugimoto
Speaker 2: "A New Option for Early Cancer Detection: Saliva Cancer Risk Test 'SalivaChecker'" - Remi Onuma
From Oral Care to Systemic Health: Salivatech's Story of Enhancing Health Span
Recent studies show that poor oral care is not only a cause of tooth decay and periodontal disease but can also trigger serious systemic diseases. Salivatech believes that by incorporating saliva testing into routine oral care at dental clinics, patients can be connected to appropriate medical treatment, contributing to increased health span.
Covering 6 Types of Cancer with One Drop of Saliva
SalivaChecker® can evaluate the risk of 6 types of cancer simultaneously: oral cancer, pancreatic cancer, lung cancer, stomach cancer, colorectal cancer, and breast cancer (women only).
Bridging from 'Notice' to 'Appropriate Medical Care'
By testing at dental clinics, which are visited regularly, potential cancer risks can be visualized even in the asymptomatic stage. The company constructs a mechanism to smoothly bridge patients with high risk scores to appropriate medical institutions.
Seminar Survey: Over 85% Satisfied
- Participant satisfaction was 85.2%.
- Diverse participants: Dentists (18.5%), Dental Hygienists (30.9%), Nurses (30.9%).
- Facility types: Hospitals (61.3%), Dental Clinics (10.0%).
- Practicality: 72.7% found the test 'useful' for clinical work.
The seminar highlighted the utility of saliva testing in the dental and oral care field, systemic cancer risk assessment through oral care, and bridging patients to appropriate medical treatment to increase health span, drawing significant interest from medical professionals.
Seminar Overview
Seminar Title: Luncheon Seminar "Unlocking Systemic Signals through Oral Care"
Speaker 1: "Perspectives Connecting Oral Care and Systemic Management" - Masahiro Sugimoto
Speaker 2: "A New Option for Early Cancer Detection: Saliva Cancer Risk Test 'SalivaChecker'" - Remi Onuma
From Oral Care to Systemic Health: Salivatech's Story of Enhancing Health Span
Recent studies show that poor oral care is not only a cause of tooth decay and periodontal disease but can also trigger serious systemic diseases. Salivatech believes that by incorporating saliva testing into routine oral care at dental clinics, patients can be connected to appropriate medical treatment, contributing to increased health span.
Covering 6 Types of Cancer with One Drop of Saliva
SalivaChecker® can evaluate the risk of 6 types of cancer simultaneously: oral cancer, pancreatic cancer, lung cancer, stomach cancer, colorectal cancer, and breast cancer (women only).
Bridging from 'Notice' to 'Appropriate Medical Care'
By testing at dental clinics, which are visited regularly, potential cancer risks can be visualized even in the asymptomatic stage. The company constructs a mechanism to smoothly bridge patients with high risk scores to appropriate medical institutions.
Seminar Survey: Over 85% Satisfied
- Participant satisfaction was 85.2%.
- Diverse participants: Dentists (18.5%), Dental Hygienists (30.9%), Nurses (30.9%).
- Facility types: Hospitals (61.3%), Dental Clinics (10.0%).
- Practicality: 72.7% found the test 'useful' for clinical work.
FAQ
サリバチェッカー®で何が分かりますか？
一度のだ液採取で口腔がん、膵がん、肺がん、胃がん、大腸がん、乳がん（女性のみ）の計6種のがんリスクを同時に評価できます。
歯科医院でがんリスクを検査するメリットは何ですか？
定期的に通院する歯科医院で検査を行うことで、自覚症状のない段階から潜在的ながんリスクを可視化でき、高リスク者に専門医療機関への橋渡しができる仕組みです。
セミナー参加者の満足度はどの程度でしたか？
参加者アンケートにおいて、総合的な満足度は85.2%（大変満足・満足の合計）と極めて高い評価を得ました。
セミナーの主な登壇者は誰ですか？
サリバテック取締役の杉本昌弘氏（慶應義塾大学教授）と、同社医療機関営業の小沼麗美氏が登壇しました。
サリバテックが目指す健康寿命増進のストーリーとは？
日常的な口腔ケアにだ液検査を組み込み、全身のがんリスク管理を行うことで、病気の早期発見を実現し、地域住民が長く元気に暮らせる社会への貢献を目指しています。